今日，Ascendis Pharma 宣布，美国 FDA 已加速批准每周一次那韦培肽（Navepegritide，商品名 YUVIWEL®）的新药上市申请，用于治疗2 岁及以上患有软骨发育不全的儿童患者。维升药业拥有那韦培肽在大中华区的独家开发、生产及商业化权利。截图来源：Ascendis官网软骨发育不全症是一种罕见遗传性疾病。该病由成纤维细胞生长因子受体 3（FGFR3）基因突变引发，会导致 ...
Source Link今日，Ascendis Pharma 宣布，美国 FDA 已加速批准每周一次那韦培肽（Navepegritide，商品名 YUVIWEL®）的新药上市申请，用于治疗2 岁及以上患有软骨发育不全的儿童患者。维升药业拥有那韦培肽在大中华区的独家开发、生产及商业化权利。截图来源：Ascendis官网软骨发育不全症是一种罕见遗传性疾病。该病由成纤维细胞生长因子受体 3（FGFR3）基因突变引发，会导致 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.